Disorder |
Chromosome or gene |
Type |
Reference |
Prevalence |
1p36 deletion syndrome |
1 |
D |
|
1:7,500 |
1q21.1 deletion syndrome |
1q21.1 |
D |
|
|
2q37 deletion syndrome |
2q37 |
D |
|
|
5q deletion syndrome |
5q |
D |
|
|
5,10-methenyltetrahydrofolate synthetase deficiency |
MTHFS |
|
[2] |
|
7p22.1 microduplication syndrome |
7p22.1 |
|
|
|
17q12 microdeletion syndrome |
17q12 |
|
[3][4] |
1:14,000-62,500 |
17q12 microduplication syndrome |
17q12 |
|
[5] |
|
18p deletion syndrome |
18p |
D |
|
1:50,000 |
21-hydroxylase deficiency |
6p21.3 |
recessive |
|
1:15,000 |
Alpha 1-antitrypsin deficiency |
14q32 |
co-dominant, |
|
1:2,500-5,000 |
AAA syndrome (achalasia–addisonianism–alacrima syndrome) |
AAAS |
recessive |
[6] |
1:1,000,000 |
Aarskog–Scott syndrome |
FGD1 |
X-linked recessive |
|
1:25,000 |
ABCD syndrome |
EDNRB |
recessive |
|
1:18,000-20,000 |
Absence deformity of leg-cataract syndrome |
|
|
|
|
Aceruloplasminemia |
CP (3p26.3) |
recessive |
|
1:2,000,000 |
Acheiropodia |
LMBR1 |
recessive |
|
|
Achondrogenesis type II |
COL2A1 (12q13.11) |
dominant |
|
1:40,000-60,000 |
Achondroplasia | FGFR3 (4p16.3) | dominant |
|
1:27,500 |
Acute intermittent porphyria | HMBS | dominant and recessive forms |
|
1:500-50,000 |
Adenylosuccinate lyase deficiency | ADSL |
recessive |
|
|
Adrenoleukodystrophy | ABCD1 (X) | recessive |
|
1:17,000 |
Alagille syndrome | JAG1, NOTCH2 |
dominant |
[7] |
1:30,000-50,000 |
ADULT syndrome |
TP63 |
dominant |
|
|
Aicardi–Goutières syndrome | TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, IFIH1 |
|
|
1:19,500,000 |
Albinism | | |
|
1:18,000-20,000 |
Alexander disease | GFAP | |
|
1:15,600,000 |
Alfi's syndrome |
9p |
monosomy |
|
1:50,000 |
Alkaptonuria | HGD | |
|
1:250,000-1,000,000 |
Alport syndrome | 10q26.13 COL4A3, COL4A4, and COL4A5 | |
|
1:5,000-10,000 |
Alternating hemiplegia of childhood |
ATP1A3 |
|
|
1:1,000,000 |
Aortic arch anomaly - peculiar facies - intellectual disability |
|
dominant |
|
|
Amish lethal microcephaly |
SLC25A19 |
recessive |
|
|
Amyotrophic lateral sclerosis – Frontotemporal dementia | C9orf72, SOD1, FUS, TARDBP, CHCHD10, MAPT |
|
|
1:100,000 |
Angel-shaped phalango-epiphyseal dysplasia |
GDF5 |
dominant |
|
|
Alström syndrome | ALMS1 | |
|
1:8,600,000 |
Alzheimer's disease | PSEN1, PSEN2, APP, APOEε4 |
|
|
1:177 |
Amelogenesis imperfecta | | |
|
1:14,000 |
Aminolevulinic acid dehydratase deficiency porphyria |
ALAD |
|
|
1:780,000,000 |
Androgen insensitivity syndrome | | |
|
1:20,000-50,000 |
Angelman syndrome | UBE3A | |
|
1:12,000-20,000 |
Aphalangy-syndactyly-microcephaly syndrome |
|
dominant |
|
|
Apert syndrome |
FGFR2 |
|
|
1:65,000-80,000 |
Arthrogryposis–renal dysfunction–cholestasis syndrome | VPS33B |
|
|
1:78,000,000 |
Ataxia telangiectasia | ATM | |
|
1:40,000-1,000,000 |
Axenfeld syndrome |
PITX2, FOXO1A, FOXC1, PAX6 |
|
|
1:200,000 |
Bainbridge–Ropers syndrome |
ASXL3 |
de novo |
|
|
Beare–Stevenson cutis gyrata syndrome | 10q26, FGFR2 | |
|
1:390,000,000 |
Beckwith–Wiedemann syndrome |
IGF-2, CDKN1C, H19, KCNQ1OT1 |
|
|
1:15,000 |
Benjamin syndrome | | |
|
1:20,000,000 |
biotinidase deficiency | BTD | |
|
1:110,000,000 |
Björnstad syndrome |
BCS1L |
|
|
1:260,000,000 |
Blepharophimosis intellectual disability syndromes |
|
|
|
|
Bloom syndrome | 15q26.1 | |
|
1:480,000 |
Birt–Hogg–Dubé syndrome | 17 FLCN | |
|
1:19,500,000 |
Brody myopathy |
ATP2A1 |
|
|
1:10,000,000 |
Brunner syndrome |
MAOA |
|
|
1:500,000,000 |
CADASIL syndrome | NOTCH3 | P |
|
1:156,000,000 |
Cat eye syndrome |
22 |
|
|
1:74,000 |
CRASIL syndrome |
HTRA1 |
|
|
1:156,000,000 |
Chronic granulomatous disorder | | |
|
1:200,000 |
Campomelic dysplasia | X 17q24.3–q25.1 | C |
|
1:40,000-200,000 |
Camptodactyly-taurinuria syndrome |
|
dominant |
|
|
Canavan disease | ASPA | |
|
1:6,400-13,500 |
Carpenter syndrome |
RAB23 |
|
|
1:1,000,000 |
CDKL5 deficiency disorder |
CDKL5 |
|
[8] |
1:40,000-60,000[8] |
Cerebral dysgenesis–neuropathy–ichthyosis–keratoderma syndrome (CEDNIK) | SNAP29 | |
|
<1:1,000,000[9] |
Cleft palate short stature vertebral anomalies syndrome |
|
|
|
|
Combined malonic and methylmalonic aciduria (CMAMMA) |
ACSF3 |
recessive |
[10][11] |
1:30,000[10] |
Combined malonic and methylmalonic aciduria (CMAMMA) |
MLYCD |
recessive |
|
|
Congenital muscular dystrophy-infantile cataract-hypogonadism syndrome |
|
recessive |
|
|
Cystic fibrosis | CFTR (7q31.2) | D or S |
[12] |
1:100,000 |
Charcot–Marie–Tooth disease | PMP22, MFN2 |
|
|
1:2,500 |
CHARGE syndrome | CHD7 | |
|
1:8,500-10,000 |
Chédiak–Higashi syndrome | LYST | recessive |
|
1:39,000,000 |
Chondrodysplasia, Grebe type |
GDF5 |
autosomal recessive |
[13] |
|
Cleidocranial dysostosis |
RUNX2 |
|
|
1:7,800 |
Cockayne syndrome | ERCC6, ERCC8 |
|
|
1:2,600-3,900 |
Coffin–Lowry syndrome | X RPS6KA3 |
|
|
1:40,000-50,000 |
Cohen syndrome | COH1 |
|
|
1:7,800,000 |
Collagenopathy, types II and XI | COL11A1, COL11A2, COL2A1 |
|
|
|
Congenital insensitivity to pain with anhidrosis (CIPA) |
NTRK1 |
|
|
|
Congenital muscular dystrophy |
multiple |
dominant or recessive |
[14] |
|
Corneal dystrophy-perceptive deafness syndrome |
SLC4A11 |
autosomal recessive |
[15] |
|
Cornelia de Lange syndrome (CDLS) |
HDAC8, SMC1A, NIPBL, SMA3, RAD21 |
|
|
1:10,000-30,000 |
Cowden syndrome | PTEN |
|
|
1:200,000 |
CPO deficiency (coproporphyria) | CPOX |
|
|
|
Cranio-lenticulo-sutural dysplasia | 14q13–q21 |
|
|
|
Cri du chat | 5p15.2 | D |
[16][17] |
1:37,000-50,000 |
Crohn's disease | 16q12 | P |
|
|
Crouzon syndrome | FGFR2, FGFR3 | |
|
1.6:100,000 |
Crouzonodermoskeletal syndrome (Crouzon syndrome with acanthosis nigricans) | FGFR3 |
|
|
1:1,000,000 |
Currarino syndrome |
HLXB9 |
dominant |
|
1:100,000 |
Darier's disease |
ATP2A2 |
|
|
1:30,000-100,000 |
Dent's disease (Genetic hypercalciuria) | Xp11.22 CLCN5, OCRL | |
|
|
Denys–Drash syndrome |
WT1 |
|
|
|
De Grouchy syndrome | 18q | D |
|
|
Dolichonychia |
|
|
|
|
Down syndrome |
21 |
C |
|
1:1,000-1,100 1:1,200 (U.S.) |
DiGeorge syndrome | 22q11.2 | D |
|
1:4,000 |
Distal hereditary motor neuropathies, multiple types | HSPB8, HSPB1, HSPB3, GARS, REEP1, IGHMBP2, SLC5A7, DCTN1, TRPV4, SIGMAR1 | |
|
|
Distal muscular dystrophy |
Dysferlin, TIA1, GNE (gene), MYH7, Titin, MYOT, MATR3, unknown |
Dominant or recessive |
[18] |
|
Duchenne muscular dystrophy |
Dystrophin |
X-linked recessive |
[19] |
|
Dravet syndrome | SCN1A, SCN2A | |
|
1:20,000-40,000 |
Ectrodactyly-polydactyly syndrome |
|
|
|
|
Edwards syndrome |
18 |
trisomy |
|
1:5,000 |
Ehlers–Danlos syndrome | COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, TNXB, ADAMTS2, PLOD1, B4GALT7, DSE |
dominant |
|
1:5,000 |
Emanuel syndrome |
11, 22 |
partial trisomy |
|
|
Emery–Dreifuss syndrome |
EMD, LMNA, SYNE1, SYNE2, FHL1, TMEM43 |
|
|
|
Epidermolysis bullosa |
KRT5, KRT14, DSP, PKP1, JUP, PLEC1, DST, EXPH5, TGM5, LAMA3, LAMB3, LAMC2, COL17A1, ITGA6, ITGA4, ITGA3, COL7A1, FERMT1 |
dominant or recessive |
[20][21] |
11.08:1,000,000 |
Erythropoietic protoporphyria |
FECH |
|
|
1:75,000-200,000 |
Fanconi anemia (FA) |
FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM, FANCN, FANCP, FANCS, RAD51C, XPF |
|
|
1:130,000 |
Fabry disease | GLA (Xq22.1) | P |
|
1:117,000-476,000 |
Factor V Leiden thrombophilia | | |
|
|
Fatal familial insomnia |
PRNP |
dominant |
|
|
Familial adenomatous polyposis | APC | |
|
1:10,000-15,000 |
Familial dysautonomia | IKBKAP |
|
|
|
Familial Creutzfeld–Jakob disease |
PRNP |
dominant |
|
|
Familial episodic pain syndrome |
TRPA1, SCN10A, SCN11A |
dominant |
|
|
Familial thoracic aortic aneurysm and aortic dissection |
FOXE3, SMAD2, LOX, MAT2A, ELN, HEY2, TGFB3, TGFBR1, TGFBR2, FBN1, ACTA2, MYLK, SMAD3, PRKG1, MFAP5, TGFB2, SMAD4, MYH11 |
dominant |
|
|
Feingold syndrome |
MYCN |
|
|
|
FG syndrome | MED12 |
|
|
|
FBXW7 neurodevelopmental syndrome |
FBXW7 |
|
|
|
Fibular aplasia-ectrodactyly syndrome |
|
dominant |
|
|
Fine-Lubinsky syndrome |
MAF |
recessive |
|
|
Fragile X syndrome |
FMR1 |
T |
|
1:4,000 males
1:8,000 females |
Friedreich's ataxia | FXN | T |
|
1:50,000 (U.S.) |
G6PD deficiency | | |
|
|
Galactosemia | GALT, GALK1, GALE | |
|
|
Gaucher disease | GBA (1) | |
|
1:20,000 |
Gerstmann–Sträussler–Scheinker syndrome |
PRNP |
dominant |
|
|
Gillespie syndrome |
PAX6 |
|
|
|
Glutaric aciduria, type I and type 2 |
GCDH, ETFA, ETFB, ETFDH |
recessive |
|
|
GRACILE syndrome |
BCS1L |
|
|
|
GRIN2B-related neurodevelopmental disorder |
GRIN2B |
|
|
|
Griscelli syndrome | MYO5A, RAB27A, MLPH |
|
|
|
Gustavson syndrome |
|
|
|
|
Hailey–Hailey disease |
ATP2C1 (3) |
|
|
|
Harlequin type ichthyosis | ABCA12 | |
|
|
Hemochromatosis type 1 | HFE (chromosome 6) | recessive | . | 1:200 (Northern Europe), 1:300 (Northern America) |
Hemochromatosis type 2A | HJV (or HFE2A) (chromosome 1) | recessive |
|
|
Hemochromatosis type 2B | HAMP (or HFE2B) (chromosome 19) | recessive |
|
|
Haemochromatosis type 3 | TFR2 (or HFE3) (chromosome 7) | recessive |
|
|
Hemochromatosis type 4 | SLC40A1 (or HFE4) (chromosome 2) | dominant |
|
|
Hemochromatosis type 5 | FTH1 (chromosome 11) | dominant |
|
|
Hemophilia | FVIII |
|
|
1:7,500 males (hemophilia A)
1:40,000 males (hemophilia B) |
Hepatoerythropoietic porphyria | UROD |
|
|
|
Hereditary coproporphyria | 3q12 | P |
|
|
Hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu syndrome) | ENG, ACVRL1, MADH4 | |
|
1:5,000 [22] |
Hereditary inclusion body myopathy | GNE, MYHC2A, VCP, HNRPA2B1, HNRNPA1 |
|
|
|
Hereditary multiple exostoses | EXT1, EXT2, EXT3 | |
|
1:50,000 |
Hereditary spastic paraplegia (infantile-onset ascending hereditary spastic paralysis) | AP4M1, AP4S1, AP4B1, AP4E1 |
autosomal dominant, autosomal recessive or X-linked recessive |
|
2-6:100,000 |
Hermansky–Pudlak syndrome | HPS1, HPS3, HPS4, HPS5, HPS6, HPS7, AP3B1 |
|
|
1:500,000 |
Hereditary neuropathy with liability to pressure palsies (HNPP) | PMP22 | |
|
|
Heterotaxy |
NODAL, NKX2-5, ZIC3, CCDC11, CFC1, SESN1 |
|
|
|
Homocystinuria | CBS (gene) |
recessive |
[23] |
|
Huntington's disease |
chromosome 4 HTT gene |
autosomal dominant |
|
1:10,000 in US |
Hunter syndrome |
IDS |
|
|
1:100,000-150,000 males |
Hurler syndrome |
IDUA |
|
|
1:100,000 |
Hutchinson–Gilford progeria syndrome | LMNA |
|
|
1:18,000,000 |
Hyperlysinemia |
AASS |
recessive |
|
|
Hyperoxaluria, primary | AGXT, GRHPR, DHDPSL |
|
|
|
Hyperphenylalaninemia | 12q |
|
|
|
Hypoalphalipoproteinemia (Tangier disease) |
ABCA1 |
|
|
|
Hypochondrogenesis | COL2A1 |
|
|
|
Hypochondroplasia |
FGFR3 (4p16.3) |
|
|
|
Immunodeficiency–centromeric instability–facial anomalies syndrome (ICF syndrome) | 20q11.2 | |
|
|
Incontinentia pigmenti | IKBKG (Xq28) | P |
|
|
Infantile cerebral and cerebellar atrophy with postnatal progressive microcephaly |
MED17 |
recessive |
|
|
Ischiopatellar dysplasia | TBX4 | dominant |
|
|
Isodicentric 15 | 15q11–14 | Inv dup |
|
1:30,000 [24] |
PRICKLE1-related progressive myoclonus epilepsy with ataxia |
PRICKLE1 |
dominant or recessive |
|
|
Jackson–Weiss syndrome | FGFR2 | |
|
|
Jacobsen syndrome |
11 |
|
|
1:100,000 |
Joubert syndrome | INPP5E, TMEM216, AHI1, NPHP1, CEP290, TMEM67, RPGRIP1L, ARL13B, CC2D2A, OFD1, TMEM138, TCTN3, ZNF423, AMRC9 |
|
|
|
Juvenile-onset dystonia |
ACTB, IMPDH2 |
dominant |
|
|
Juvenile primary lateral sclerosis (JPLS) | ALS2 | |
|
|
Keloid disorder | | |
|
|
KIF1A-Associated neurological disorder |
KIF1A (2q37.3) |
Dominant negative |
|
|
Kleefstra syndrome |
9q34 |
D |
|
|
Kniest dysplasia | COL2A1 | |
|
1:1,000,000 |
Kosaki overgrowth syndrome | PDGFRB | |
|
|
Krabbe disease | GALC | |
|
1:100,000 |
Kufor–Rakeb syndrome |
ATP13A2 |
|
|
|
LCAT deficiency |
LCAT |
|
|
|
Lesch–Nyhan syndrome | HPRT (X) | |
|
1:380,000 |
Li–Fraumeni syndrome | TP53 |
|
|
|
Limb-Girdle Muscular Dystrophy |
Multiple |
dominant or recessive |
[25][26] |
1:14,500-123,000 |
Lynch syndrome | MSH2, MLH1, MSH6, PMS2, PMS1, TGFBR2, MLH3 |
|
|
1:279 |
lipoprotein lipase deficiency | | recessive |
|
1:1,000,000 |
Malignant hyperthermia |
RYR1 (19q13.2) |
dominant |
|
1:5,000-100,000 |
Maple syrup urine disease |
BCKDHA, BCKDHB, DBT, DLD |
recessive |
|
|
Marfan syndrome | 15q | dominant |
|
1:5,000-10,000 |
Maroteaux–Lamy syndrome |
ARSB |
recessive |
|
1:43,261-1,505,160 |
McCune–Albright syndrome | 20 q13.2–13.3 | |
|
1:100,000-1,000,000 |
McLeod syndrome | XK (X) | |
|
0.5-1:100,000 |
MEDNIK syndrome | AP1S1 | D |
[27][28] |
|
Mediterranean fever, familial | MEFV | |
|
|
Menkes disease | ATP7A (Xq21.1) | |
|
1:100,000-250,000 |
Methemoglobinemia | | |
|
|
Methylmalonic acidemia | MMAA, MMAB, MMACHC, MMADHC, LMBRD1, MUT |
recessive |
|
1:48,000 |
Micro syndrome | RAB3GAP (2q21.3) | |
|
|
Microcephaly | ASPM (1q31) | P |
|
|
Miller-Dieker syndrome |
17p13.3 |
D |
|
1:100,000 |
Morquio syndrome | GALNS, GLB1 | |
|
1:200,000-300,000 |
Mowat–Wilson syndrome | ZEB2 (2) | |
|
|
Muenke syndrome | FGFR3 | |
|
1:30,000 |
Multiple endocrine neoplasia type 1 (Wermer's syndrome) | MEN1 | dominant |
|
|
Multiple endocrine neoplasia type 2 |
RET |
dominant |
|
|
Muscular dystrophy | multiple |
AR, AD, X-linked |
|
|
Muscular dystrophy, Duchenne and Becker type | | |
|
|
Myostatin-related muscle hypertrophy | MSTN |
|
|
|
Myotonic dystrophy | DMPK, CNBP | dominant or T |
|
1:8,000 |
Natowicz syndrome |
HYAL1 | |
|
<1:1,000,000 |
|
Neurofibromatosis type I | 17q11.2 | |
|
|
Neurofibromatosis type II | NF2 (22q12.2) | |
|
|
Niemann–Pick disease | SMPD1, NPA, NPB, NPC1, NPC2 | |
|
1:250,000 (types A and B)
1:150,000 (type C) |
Nonketotic hyperglycinemia | GLDC, AMT, GCSH |
recessive |
|
1:60,000 |
Nonsyndromic deafness | | |
|
|
Noonan syndrome | PTPN11, KRAS, SOS1, RAF1, NRAS, HRAS, BRAF, SHOC2, MAP2K1, MAP2K2, CBL | dominant |
|
1:1,000 |
Norman–Roberts syndrome |
RELN |
recessive |
|
|
Ogden syndrome |
X |
P |
|
|
Omenn syndrome |
RAG1, RAG2 |
recessive |
|
|
Osteogenesis imperfecta | COL1A1, COL1A2, IFITM5 |
dominant |
|
1:15,000-20,000 |
Ostravik-Lindemann-Solberg syndrome |
2p15 |
autosomal recessive |
[29] |
|
Pantothenate kinase-associated neurodegeneration | PANK2 (20p13–p12.3) | recessive |
|
1-3:1,000,000 |
Patau syndrome (Trisomy 13) | 13 | trisomy |
|
|
PCC deficiency (propionic acidemia) | PC | recessive |
|
1:250,000 |
Porphyria cutanea tarda (PCT) | UROD | dominant |
|
1:10,000 |
Pendred syndrome | PDS (7) | recessive |
|
|
Peutz–Jeghers syndrome | STK11 |
dominant |
|
1:25,000-300,000 |
Pfeiffer syndrome | FGFR1, FGFR2 | dominant |
|
1:100,000 |
Phelan-McDermid syndrome |
22q13 |
D |
|
|
Phenylketonuria | PAH | recessive |
|
1:12,000 |
Pipecolic acidemia |
AASDHPPT |
recessive |
|
|
Pitt–Hopkins syndrome |
TCF4 (18) |
dominant, de novo |
|
1:11,000-41,000 |
Polycystic kidney disease |
PKD1 (16) or PKD2 (4) |
P |
|
|
Polycystic ovary syndrome (PCOS) | | |
|
|
Porphyria | | |
|
1-100:50,000 |
Prader–Willi syndrome | 15 | paternal imprinting |
|
1:10,000-30,000 |
Primary ciliary dyskinesia (PCD) | DNAI1, DNAH5, TXNDC3, DNAH11, DNAI2, KTU, RSPH4A, RSPH9, LRRC50 |
recessive |
|
1:32,000 |
Primary pulmonary hypertension | | |
|
|
Protein C deficiency | PROC |
dominant |
[30] |
1:20,000 |
Protein S deficiency | PROS1 |
dominant |
|
|
Proximal 18q deletion syndrome |
18q |
D |
|
|
Pseudo-Gaucher disease | | |
|
|
Pseudoxanthoma elasticum | ABCC6 |
recessive |
|
1:25,000 |
Retinitis pigmentosa |
RP1, RP2, RPGR, PRPH2, IMPDH1, PRPF31, CRB1, PRPF8, TULP1, CA4, HPRPF3, ABCA4, EYS, CERKL, FSCN2, TOPORS, SNRNP200, PRCD, NR2E3, MERTK, USH2A, PROM1, KLHL7, CNGB1, TTC8, ARL6, DHDDS, BEST1, LRAT, SPARA7, CRX |
dominant or recessive |
|
1:4,000 |
Rett syndrome | MECP2 |
dominant, often de novo |
|
1:8,500 females |
Roberts syndrome |
ESCO2 |
recessive |
|
|
Rubinstein–Taybi syndrome (RSTS) | CREBBP |
dominant |
|
1:125,000-300,000 |
Sandhoff disease | HEXB | recessive |
|
|
Sanfilippo syndrome |
SGSH, NAGLU, HGSNAT, GNS |
|
|
1:70,000 |
Scheuermann's disease |
1q21-q22 or 7q22 |
autosomal dominant |
|
1:45 |
Schwartz–Jampel syndrome | HSPG2 |
recessive |
|
|
Sjogren-Larsson syndrome |
ALDH3A2 |
Autosomal-recessive |
, , Archived 2018-01-23 at the Wayback Machine |
|
Skin fragility-woolly hair-palmoplantar keratoderma syndrome |
DSP |
|
|
|
Spondyloepiphyseal dysplasia congenita (SED) | COL2A1 |
dominant |
|
|
Shprintzen–Goldberg syndrome | FBN1 | dominant |
|
|
Sickle cell anemia | 11p15 | P |
|
|
Siderius X-linked mental retardation syndrome | PHF8 | X-Linked Recessive |
[31] |
|
Sideroblastic anemia |
ABCB7, SLC25A38, GLRX5 |
recessive |
|
|
Sly syndrome |
GUSB |
recessive |
|
1:250,000 |
Smith–Lemli–Opitz syndrome | DHCR7 |
recessive |
|
1:20,000-60,000 |
Smith–Magenis syndrome | 17p11.2 |
dominant |
|
1:15,000-25,000 |
Snyder–Robinson syndrome | Xp21.3-p22.12 |
recessive |
|
<1:1,000,000 |
Spinal muscular atrophy | 5q |
|
|
1:10,000 |
Spinocerebellar ataxia (types 1–29) | ATXN1, ATXN2, ATXN3, PLEKHG4, SPTBN2, CACNA1A, ATXN7, ATXN8OS, ATXN10, TTBK2, PPP2R2B, KCNC3, PRKCG, ITPR1, TBP, KCND3, FGF14 |
dominant, recessive or T |
|
|
Split hand split foot-nystagmus syndrome |
|
dominant |
|
|
SSB syndrome (SADDAN) | FGFR3 |
dominant |
|
|
Stargardt disease (macular degeneration) |
ABCA4, CNGB3, ELOVL4, PROM1 |
dominant or recessive |
|
1-1.28:10,000 |
Stickler syndrome (multiple forms) | COL11A1, COL11A2, COL2A1, COL9A1 | dominant or recessive |
|
1:7,500-9,000 (U.S.) |
Strudwick syndrome (spondyloepimetaphyseal dysplasia, Strudwick type) | COL2A1 | dominant |
|
|
Tay–Sachs disease | HEXA (15) | recessive |
|
|
Tetrahydrobiopterin deficiency | GCH1, PCBD1, PTS, QDPR, MTHFR, DHFR |
recessive |
|
|
Thanatophoric dysplasia | FGFR3 | dominant |
|
1:60,000 |
Thickened earlobes-conductive deafness syndrome |
|
|
|
|
Treacher Collins syndrome | 5q32–q33.1 (TCOF1, POLR1C, or POLR1D) | dominant |
|
1:50,000 |
Tuberous sclerosis complex (TSC) |
TSC1, TSC2 |
dominant |
|
7-12:100,000 |
Turner syndrome | X | monosomy |
|
1:2,000-2,500 live female births |
Usher syndrome | MYO7A, USH1C, CDH23, PCDH15, USH1G, USH2A, GPR98, DFNB31, CLRN1 | recessive |
|
3-6:100,000 (type I) |
Variegate porphyria | PPOX | dominant |
|
|
Viljoen-Kallis-Voges syndrome |
|
recessive |
|
|
von Hippel–Lindau disease | VHL |
dominant |
|
1:36,000 |
von Willebrand disease | VWF | dominant |
|
1:10,000 |
Waardenburg syndrome | PAX3, MITF, WS2B, WS2C, SNAI2, EDNRB, EDN3, SOX10 |
dominant |
|
1:42,000 |
Warkany syndrome 2 |
8 |
trisomy |
|
|
Weissenbacher–Zweymüller syndrome | COL11A2 | recessive |
|
|
Weyer's ulnar ray/oligodactyly syndrome |
|
recessive |
|
|
Williams syndrome | 7q11.23 | dominant |
|
1:10,000 |
Wilson disease | ATP7B | recessive |
|
1:30,000 |
Woodhouse–Sakati syndrome |
C2ORF37 (2q22.3–q35) | recessive |
|
|
Wolf–Hirschhorn syndrome | 4p16.3 | dominant, often de novo |
|
1:50,000 |
Xeroderma pigmentosum | 15 ERCC4 | recessive |
|
|
X-linked intellectual disability and macroorchidism (fragile X syndrome) | X | |
|
|
X-linked spinal-bulbar muscle atrophy (spinal and bulbar muscular atrophy) | X | |
|
|
Xp11.2 duplication syndrome |
Xp11.2 | D |
[32] |
1:1,000,000 |
X-linked severe combined immunodeficiency (X-SCID) | X | |
|
|
X-linked sideroblastic anemia (XLSA) | ALAS2 (X) | |
|
|
47,XXX (triple X syndrome) |
X |
C |
|
1:1,000 females |
XXXX syndrome (48, XXXX) | X | |
|
1:50,000 females |
XXXXX syndrome (49,XXXXX) |
X |
|
|
1:85,000-250,000 females |
XXXXY syndrome (49,XXXXY) |
X |
|
|
1:85,000-100,000 males |
XYY syndrome (47,XYY) |
Y |
|
|
1:1,000 male births |
XXYY syndrome (48,XXYY) |
X, Y |
|
|
1:18,000-40,000 males |
XYYY syndrome (48,XYYY) |
Y |
|
|
|
XXXY syndrome (48,XXXY) |
X |
|
|
1:50,000 males |
XYYYY syndrome (49,XYYYY) |
Y |
|
|
1:1,000,000 males |
Zellweger syndrome |
PEX1, PEX2, PEX3, PEX5, PEX6, PEX10, PEX12, PEX13, PEX14, PEX16, PEX19, PEX26 |
recessive |
|
|